Cormorant Asset Management’s Vaxcyte PCVX Stock Holding History

Cormorant Asset Management’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$5.81M	Sell	100,000 -25,000	-20%	-$1.36M	0.29%	44
2025 Q4	$5.77M	Sell	125,000 -50,000	-29%	-$2.24M	0.27%	33
2025 Q3	$6.3M	Hold	175,000	–	–	0.43%	34
2025 Q2	$5.69M	Hold	175,000	–	–	0.42%	36
2025 Q1	$6.61M	Sell	175,000 -250,000	-59%	-$20M	0.5%	35
2024 Q4	$34.8M	Sell	425,000 -575,000	-58%	-$57.1M	1.91%	14
2024 Q3	$114M	Sell	1,000,000 -100,000	-9%	-$9.01M	6.06%	2
2024 Q2	$83.1M	Buy	1,100,000 +415,000	+61%	+$28.2M	4.8%	4
2024 Q1	$46.8M	Buy	685,000 +20,000	+3%	+$1.38M	2.05%	14
2023 Q4	$41.8M	Hold	665,000	–	–	1.99%	14
2023 Q3	$33.9M	Hold	665,000	–	–	1.98%	13
2023 Q2	$33.2M	Buy	665,000 +390,000	+142%	+$18.5M	1.86%	11
2023 Q1	$10.3M	Sell	275,000 -50,000	-15%	-$2.12M	0.68%	38
2022 Q4	$15.6M	Buy	+325,000	New	+$12.8M	1.04%	31

Other funds holding PCVX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Cormorant Asset Management's PCVX Position: Q1 2026 in Review

Cormorant Asset Management reduced its Vaxcyte (PCVX) stake by 20% in Q1 2026, selling an estimated $1.36M and leaving 100,000 shares worth $5.81M. The position accounts for 0.29% of the portfolio, ranked #44.

Cormorant Asset Management first reported a position in PCVX in Q4 2022 and has held it in 14 quarters since. The position peaked at $114M in Q3 2024. 336 funds tracked by Wall St. Rank hold PCVX as of Q1 2026.

Cormorant Asset Management held 100,000 shares of Vaxcyte worth $5.81M as of Q1 2026.
Cormorant Asset Management sold 25,000 Vaxcyte shares in Q1 2026, an estimated $1.36M.
Vaxcyte made up 0.29% of Cormorant Asset Management's portfolio in Q1 2026, its #44 holding.
Cormorant Asset Management first reported a position in Vaxcyte in Q4 2022 and has held it in 14 quarters since.
Cormorant Asset Management's Vaxcyte position peaked at $114M in Q3 2024.
336 funds tracked by Wall St. Rank held Vaxcyte as of Q1 2026.

Based on Cormorant Asset Management's 13F filing for Q1 2026, filed 15 May 2026.